Tempus is a startup from Eric Lefkofsky, who is the founder of GroupOn. It is designed to fight breast cancer. With this, Eric Lefkofsky will be giving doctors at the University of Chicago a better way for treating the breast cancer patients.Tempus is based in Chicago. It has got into a partnership with the Medicine Thursday at the University of Chicago. Tempus will be providing molecular sequencing along with its analysis to the breast cancer specialists at UChicago. Such kind of data will be extremely in creating personalized treatment plans for the breast cancer patients.Find him on Facebook: Click here
Eric Lefkofsky has said that Tempus will be analyzing data of nearly 1,000 breast cancer patients. This will help in identifying patterns that can help doctors and researchers to predict how their patients will be responding to specific treatment.Eric Lefkofsky had established the Lefkofsky Family Foundation in 2006. This is a private charity foundation. It provides initiatives that are able to enhance lives of people in the communities.
Eric Lefkofsky is a Trustee of Lurie Children’s Hospital of Chicago, besides The Art Institute of Chicago, as well as The Museum of Science and Industry and of the World Business Chicago.Now he wants to help UChicago by providing it data that will lead to better treatment of the patient. The fact is that breast cancer is common cancer, but there is relatively very little accessible data available on the patients who have suffered this disease. This is why physicians are forced to treat patients without having any specific genetic information. In case this information was available, it would help in making better-informed decisions that were precise. This is why partnering with Tempus will be helpful. Tempus is making efforts to build the largest of molecular data set specifically in breast cancer which will be clinically annotated.